Giotrif®
afatinib
About Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.
Professional Area
You are a Healthcare Professional or Journalists & Media Professional? Click below to be able to see and access respective content.
Product Key Facts
Indications
Non-small cell lung cancer (NSCLC)
Brand Names
Giotrif® Gilotrif®
Active ingredients
afatinib